AU2024234653A1 — Methods of treating atopic dermatitis using tapinarof
Assigned to Dermavant Sciences GmbH · Expires 2025-10-16 · 1y expired
What this patent protects
Disclosed is composition and a method for treating atopic dermatitis by applying a 1.0% tapinarof topical cream to the affected area of a subject once daily for a minimum of 8 weeks. The treatment results in a significant improvement in the vIGA-AD score, achieving at least a 2-g…
USPTO Abstract
Disclosed is composition and a method for treating atopic dermatitis by applying a 1.0% tapinarof topical cream to the affected area of a subject once daily for a minimum of 8 weeks. The treatment results in a significant improvement in the vIGA-AD score, achieving at least a 2-grade improvement from baseline and a final score of 0. Additionally, a reduction of at least 4 points in the PP-NRS score is observed during the treatment period. In some instances, the method ensures that the plasma concentration of tapinarof remains below 50 pg/mL throughout the application of the topical cream, providing an effective and safe treatment for atopic dermatitis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.